Trevi Therapeutics (TRVI) Invested Capital (2018 - 2026)

Trevi Therapeutics has reported Invested Capital for 9 years, with the latest figure at $172.1 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 73.07% year-over-year to $172.1 million; the trailing twelve-month figure through Mar 2026 stood at $172.1 million (up 73.07% YoY), and the FY2025 full-year result was $183.2 million, up 83.9% from the prior year.
• Invested Capital for Q1 2026 stood at $172.1 million, down from $183.2 million in the prior quarter.
• The five-year high for Invested Capital was $198.5 million in Q2 2025, with the low at $17.5 million in Q1 2022.
• Average Invested Capital over 5 years is $107.8 million, with a median of $99.5 million recorded in 2025.
• Year-over-year, Invested Capital jumped 656.02% in 2022 and tumbled 34.19% in 2024.
• Tracing TRVI's Invested Capital over 5 years: stood at $114.5 million in 2022, then fell by 27.75% to $82.7 million in 2023, then increased by 20.49% to $99.6 million in 2024, then soared by 83.9% to $183.2 million in 2025, then retreated by 6.07% to $172.1 million in 2026.
• The last three Invested Capital figures came in at $172.1 million (Q1 2026), $183.2 million (Q4 2025), and $189.8 million (Q3 2025), per Business Quant data.

Peer Comparison